Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$12.02 - $21.3 $43,272 - $76,680
-3,600 Reduced 69.23%
1,600 $33.4 Million
Q1 2024

Apr 25, 2024

BUY
$7.77 - $15.66 $40,404 - $81,432
5,200 New
5,200 $76.4 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $942M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track N Verses Capital, LLC Portfolio

Follow N Verses Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of N Verses Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on N Verses Capital, LLC with notifications on news.